Skip to main content

Table 2 Clinical factors associated with the probability of loss of MR4.5

From: Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Variables No. of pts No. of events Univariate Analysis Multivariate analysis
P HR 95% CI P
Age
 < 65 years 87 30     
 ≥ 65 years 13 5 0.778    
Sex
 Male 43 18     
 Female 57 17 0.160    
First treatment
 Interferon 32 7     
 TKI 68 28 0.031 0.60 0.25 to 1.44 0.249
Frontline TKI
 Imatinib 43 19     
 Dasatinib 13 4 0.463    
 Nilotinib 9 2 0.439    
 Bosutinib 1 1 0.210    
 Poantinib 2 2 0.100    
Last TKI before discontinuation
 Imatinib 47 11     
 Dasatinib 35 16 0.021    
 Nilotinib 14 6 0.064    
 Bosutinib 2 1 0.604    
 Ponatinib 2 1 0.548    
Frontline and only TKI
 Imatinib 23 8     
 Dasatinib 13 4 0.892    
 Nilotinib 7 2 0.970    
Line of TKI
 1 line 68 18     
 > 2 line 32 17 0.007 1.43 0.64 to 3.19 0.377
Response at 3 months
 BCR-ABL/ABL < 10% (IS) 53 18     
 BCR-ABL/ABL ≥ 10% (IS) 3 2 0.213    
Transcript type
 b3a2 50 17     
 b2a2 30 10 0.866    
 b3a2 + b2a2 17 7 0.511    
Sokal score
 Low 35 10     
 Intermediate 21 9 0.261    
 High 4 0 0.999    
Reason for discontinuation
 Elective 47 15     
 Adverse effects 53 20 0.557    
Duration to achieve MR4.5
 < 17 months 47 15     
 ≥ 17 months 53 20 0.593    
Duration of MR4.5
 < 72 months 46 31     
 ≥ 72 months 54 4 < 0.001 0.11 0.03 to 0.41 0.001
Duration of TKI therapy
 < 87 months 34 22     
 ≥ 87 months 66 13 < 0.001 0.73 0.29 to 1.82 0.501
  1. CI confidence interval, HR hazard ratio, MR4.5 molecular response of 4.5-log reduction from baseline, P P value, TKI tyrosine kinase inhibitor